

GLAXOSMITHKLINE PLC
Form 6-K
February 22, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 22 February 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc

(the Company)

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.0000	13,284 (Deferred)
£0.0000	4,428 (Matching)

Aggregated information

- d) Aggregated volume Price 17,712
£0.0000
- e) Date of the transaction 2017-02-21
- f) Place of the transaction n/a

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global
Manufacturing & Supply
 - c) Initial notification/
amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.3575	6,369 (Deferred)
£16.3575	2,124 (Matching)
 - d) Aggregated information

Aggregated volume	8,493
Price	£16.3575
 - e) Date of the transaction 2017-02-21
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S A Hussain
 - b) Position/status President, Global
Pharmaceuticals
 - c) Initial notification/
amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
ISIN: GB0009252882
- b) Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
Price(s) Volume(s)
£0.0000 9,743 (Deferred)
£0.0000 3,248 (Matching)
- Aggregated information
- d) Aggregated volume Price
12,991
£0.0000
- e) Date of the transaction
2017-02-21
- f) Place of the transaction
n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name
Mr S A Hussain
- b) Position/status
President, Global
Pharmaceuticals
- c) Initial notification/
amendment
Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name
GlaxoSmithKline plc
- b) LEI
5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
ISIN: GB0009252882
- b) Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

2017 under the Company's
Deferred Annual Bonus Plan -
Deferred Bonus and Matching
Awards.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.4650	4,234 (Deferred)
	£16.4750	1,412 (Matching)

Aggregated information	
d) Aggregated volume Price	5,646 £16.4675
e) Date of the transaction	2017-02-21
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr P J T Vallance
b) Position/status	President, R&D
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
------------------------------	---

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£0.0000	26,863 (Deferred)
	£0.0000	8,954 (Matching)

Aggregated information	
d) Aggregated volume Price	35,817 £0.0000
e) Date of the transaction	2017-02-21
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr P J T Vallance
 - b) Position/status President, R&D
 - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

Price(s)	Volume(s)
£16.3575	12,879 (Deferred)
£16.3575	4,294 (Matching)
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.3575	12,879 (Deferred)
£16.3575	4,294 (Matching)
 - d) Aggregated information

Aggregated volume	Price
17,173	£16.3575
 - e) Date of the transaction 2017-02-21
 - f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 22, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc